Orthocell presents new data at international hip conference

Company News

Orthocell (ASX:OCC) will present new positive two year data from a study of its tendon cell treatment for degenerate hip (gluteal) tendons at the 3rd Melbourne International Hip Arthroscopy meeting.

The meeting is being held today and tomorrow and brings together world leading hip surgeons to discuss the latest developments and advances in hip therapy.

The study shows Orthocell’s Ortho-ATI therapy significantly improved the clinical outcome of patients with long-term gluteal tendon degeneration.

The data shows reduced pain and increased functionality at the two year review time point, following a single ultrasound guided injection of Ortho-ATI.

Orthocell is also hosting a symposium - Development of Cell Therapy Options for Hip Tendinopathy: The translation of tendinopathy from pathology to clinical treatment.

The symposium will focus on the clinical outcomes of Ortho-ATI, rehabilitation of patients following the injection, and the treatment pathways and options available to surgeons in the treatment of degenerate hip tendons.

Orthocell Managing Director Paul Anderson said: “This positive Ortho-ATI data and the symposia on the development of cell therapies to treat degenerate hip tendons provides surgeons with the positive OrthoATI clinical data, an understanding of what are the causes and pathways of degeneration, as well as an understanding of when is the right time to treat their patients with Ortho-ATI.”

Gluteal tendon injury is a very common and difficult to treat injury, affecting mostly women between the ages of 35 and 65. It can result in pain, loss of function and difficult gait, interrupted sleep and long term joint damage.

The pilot study investigated the effect of Ortho-ATI in 13 patients who had failed all previous treatment attempts with an average symptom range of 33 months.

All patients were assessed by an independent therapist out to two years and demonstrated a statistically significant improvement in pain and function at three months, which was maintained out to 24 months.

Some studies have suggested that the incidence of gluteal tendon injury in women could be as high as 25 per cent, making it one of the most debilitating degenerative injuries suffered, particularly in women over the age of 40.

“Orthocell and our world-leading stem cell regeneration therapies are providing significant relief to sufferers and as the population ages and degenerate tendon conditions become more prevalent, doctors and patients are seeking out cost effective and clinically effective treatments to alleviate symptoms that affect their mobility and quality of life,” added Mr Anderson.